Compare Kaltura Inc (KLTR) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kaltura Inc vs Merck & Co., Inc. — how do they compare? Kaltura Inc trades at $1.35 (market cap $208.27M), while Merck & Co., Inc. trades at $126.24 (market cap $307.25B). The key difference: Merck & Co., Inc. is far larger — about 1475.2× Kaltura Inc's market cap, and Merck & Co., Inc. pays a 2.73% dividend while Kaltura Inc pays none. Which is the better fit depends on your goals.
| KLTR | MRK | |
|---|---|---|
Market Cap | $208.27M | $307.25B |
Sector | Technology | Health |
52-Week High | $1.97 | $129.52 |
52-Week Low | $1.08 | $77.60 |
Enterprise Value | $190.99M | $350.66B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kaltura (KLTR) trades at $1.43, up 2.88% on the day, with a bullish technical signal. The company shows improving fundamentals, with revenue stabilizing around $180M and net losses narrowing significantly from -$68M in 2022 to -$12M in 2025. Recent quarters have consistently beaten EPS expectations, and the company has garnered multiple industry awards, highlighting its leadership in agentic digital experience platforms.
The outlook is cautiously optimistic, with a path to profitability emerging, but risks remain from high debt levels and negative ROE. Analyst sentiment is mixed but leans positive, with 44% recommending Buy. The stock's valuation appears stretched on a P/B basis, requiring sustained execution for further upside.
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
